Skip to main content
          Skip to FDA Search
          Skip to in this section menu
          Skip to footer links


U.S. flagAn official website of the United States government

					Here’s how you know
          			Dot gov**The .gov means it’s official.**Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
							      SSL**The site is secure.** The **https://** ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. 
			U.S. Food and Drug Administration
				
        Search
            Menu
							
						Search FDA
									
									Submit search 
		Featured
							Contact FDA
	                FDA Guidance Documents
	                Recalls, Market Withdrawals and Safety Alerts
	                Press Announcements
	                Warning Letters
	                Advisory Committees
	                En Español

					Products
            Food
							Drugs
							Medical Devices
							Radiation-Emitting Products
							Vaccines, Blood, and Biologics
							Animal and Veterinary
							Cosmetics
							Tobacco ProductsTopics
            About FDA
							Combination Products
							Regulatory Information
							Safety
							Emergency Preparedness
							International Programs
							News and Events
							Training and Continuing Education
							Inspections and Compliance
							Science and ResearchInformation For
            Consumers
	            Patients
	            Industry
	            Health Professionals
	            Federal, State and Local Officials 
 In this section:

                CFSAN Constituent Updates

CFSAN Constituent Updates Home
          Food
          News & Events from CFSAN
          CFSAN Constituent Updates
          FDA Releases Draft Guidance on NDI Enforcement DiscretionCFSAN Constituent Updates FDA Releases Draft Guidance on NDI Enforcement Discretion
  
  	
    Subscribe to Email Updates
    Share
    Post
    Linkedin

    Email
    PrintConstituent Update

May 19, 2022

Today, the U.S. Food and Drug Administration (FDA) announced the availability of a draft guidance on late submissions of new dietary ingredient (NDI) notifications. When finalized, the draft guidance will outline the FDA’s intent to exercise enforcement discretion, for a limited time and in limited circumstances, to encourage manufacturers and distributors to correct any past failures to submit a required NDI notification.

The FDA is aware that, in the years since the Dietary Supplement Health and Education Act of 1994 was enacted, some dietary supplement manufacturers and distributors have marketed ingredients and products for which a premarket NDI notification was required, but never submitted. In a February 2019 statement about new efforts to strengthen regulation of dietary supplements through modernization and reform, the FDA emphasized the need to ensure that our regulatory framework is flexible and comprehensive enough to adequately evaluate product safety, while promoting innovation. This draft guidance, when finalized, is an important step to foster the submission of NDI notifications and is key to this effort.

The goal of this policy, when finalized, is to encourage manufacturers and distributors to correct any past failures to submit a required NDI notification. Notifications submitted under the enforcement discretion policy will help increase the amount of safety information the FDA has about NDI-containing dietary supplements in the marketplace. The guidance also should help guide appropriate enforcement actions against those that remain out of compliance with the NDI notification requirements. The enforcement discretion policy outlined in the draft guidance relates solely to the failure to file an NDI notification; it will not apply to NDI-containing dietary supplements that would be adulterated (e.g., for safety reasons) even if an NDI notification had been timely submitted, or to any other regulatory requirements that pertain to dietary supplements.

Along with this guidance, the FDA is developing a new submission type in the CFSAN Online Submission Module called a “Catch-up New Dietary Ingredient Submission.” Once the draft guidance is finalized, interested stakeholders will be able to electronically submit their late notifications to the FDA via a Catch-up New Dietary Ingredient Submission. Although notifiers may also submit late notifications on paper, the FDA encourages the use of this electronic system for late notifications submitted under the temporary enforcement discretion policy.

For additional questions regarding the FDA’s NDI notification process, please contact the Office of Dietary Supplement Programs by email at NDIN@fda.hhs.gov.

**To Submit Comments:**

Comments on the draft guidance should be submitted within 60 days after publication in the Federal Register. You may submit electronic comments to Regulations.gov. All written comments should be identified with the docket number FDA-2022-D-0281 and with the title of the guidance document.

**For More Information:**

Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification
	Press Release: New FDA Draft Guidance Aims to Increase Safety Information About Dietary Supplement Marketplace
	How to Submit Notifications for a New Dietary Ingredient
	New Dietary Ingredients (NDI) Notification Process

                                                                                  Content current as of:
      05/19/2022
              
              
Regulated Product(s)
		 Dietary SupplementsCFSAN Constituent Updates
 Subscribe to CFSAN Constituent Updates
                        Get email updates delivered to your inbox.
    Enter your email address to subscribe:
 Footer Links
    FDA Archive
          About FDA
          Accessibility
      Visitor Information
          Website Policies / Privacy
          No FEAR Act
          Vulnerability Disclosure Policy
      FOIA
          HHS.gov
          USA.gov
    Contact FDA
      Follow FDA on Facebook
      Follow FDA on X
      Follow FDA on Instagram
      Follow FDA on LinkedIn
      View FDA videos on YouTube
      Subscribe to FDA RSS feeds
    FDA Homepage
    Contact Number
      1-888-INFO-FDA (1-888-463-6332) Back toTop